Alphatec (ATEC) Set to Announce Earnings on Wednesday

Alphatec (NASDAQ:ATEC - Get Free Report) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, October 30th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter. Alphatec has set its FY 2024 guidance at EPS.Investors interested in participating in the company's conference call can do so using this link.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The medical technology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.26) by ($0.03). The firm had revenue of $145.57 million for the quarter, compared to analyst estimates of $144.55 million. Alphatec had a negative return on equity of 816.57% and a negative net margin of 33.48%. The company's revenue was up 24.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.43) EPS. On average, analysts expect Alphatec to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Alphatec Stock Down 4.6 %

Shares of Alphatec stock traded down $0.25 during trading on Wednesday, hitting $5.13. 1,339,211 shares of the stock were exchanged, compared to its average volume of 1,862,729. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.22 and a quick ratio of 1.21. The firm's 50-day moving average price is $5.80 and its 200 day moving average price is $8.99. The stock has a market cap of $717.60 million, a price-to-earnings ratio of -3.44 and a beta of 1.39. Alphatec has a 12-month low of $4.88 and a 12-month high of $17.34.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Stifel Nicolaus lowered their price objective on Alphatec from $19.00 to $16.00 and set a "buy" rating for the company in a research report on Thursday, August 1st. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Alphatec in a research note on Thursday, August 1st. Wells Fargo & Company reduced their price objective on shares of Alphatec from $26.00 to $19.00 and set an "overweight" rating for the company in a research report on Thursday, August 1st. Morgan Stanley lowered shares of Alphatec from an "overweight" rating to an "equal weight" rating in a research note on Thursday, August 1st. Finally, Barclays began coverage on shares of Alphatec in a research report on Monday, July 8th. They issued an "overweight" rating and a $19.00 price target for the company. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $17.00.

Insider Activity

In related news, Director David M. Demski purchased 50,000 shares of the stock in a transaction that occurred on Wednesday, August 21st. The shares were purchased at an average price of $5.67 per share, with a total value of $283,500.00. Following the completion of the acquisition, the director now directly owns 288,441 shares in the company, valued at $1,635,460.47. This represents a 0.00 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 22.80% of the company's stock.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.